Vitamin D Deficiency Linked to Increased Mortality
There is a strong association between 25-hydroxyvitamin D (25[OH]D) deficiency (<50 nmol/L) and increased mortality, particularly for diabetes-related deaths.
European Society for the Study of Diabetes 55th Annual Meeting
Complete Coverage
Dapagliflozin May Lower Risk for Worsening Heart Failure
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes.
Comparison of Linagliptin With Glimepiride for Cardiovascular Safety in T2D
Treatment with linagliptin compared with glimepiride results in a noninferior risk for cardiovascular morbidity and mortality in patients with type 2 diabetes.
Lower CV Risk With Metformin vs Sulfonylureas in T2D With Reduced Kidney Function
Treatment with metformin vs sulfonylureas is associated with a reduced risk for major adverse cardiovascular events among patients with type 2 diabetes and reduced kidney function.
Liraglutide Improves Glycemic Control in Children and Adolescents With T2D
Daily liraglutide, in addition to metformin and insulin, reduces HbA1c and improves glycemic control in young patients with type 2 diabetes.
Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Potential Therapeutic Efficacy of Imeglimin in Targeting Mitochondrial Bioenergetics in T2D
Researchers at EASD 2019 presented current data and ongoing clinical trial designs for the first-in-class experimental drug, imeglimin, for the treatment of type 2 diabetes.
ADO09 Confers Better Glucose Control, Slower Gastric Emptying Than Insulin Lispro in T1D
ADO09, a coformulation of amylin analog pramlintide and A21G human insulin, is superior to insulin lispro for reducing postprandial blood glucose in patients with type 1 diabetes.
PEX168, a Novel GLP-1 Receptor Agonist, Has Favorable Efficacy and Safety Profile in T2D
Positive phase 3 efficacy and safety data were announced at EASD 2019 for a novel glucagon-like peptide-1 receptor agonist, polyethylene glycol loxenatide (PED168).
Fatty Liver Index Identifies Individuals at Risk of Developing Type 2 Diabetes
Fatty liver index is a useful and simple clinical biomarker to identify individuals at risk of developing type 2 diabetes.
Canagliflozin May Reduce Gout-Related Adverse Events, Uric Acid Levels in T2D
Researchers investigated the effects of canagliflozin on serum urate levels and gout in patients with type 2 diabetes.
Want to read more?
Please login or register first to view this content.
Next post in EASD 2019
